Yesterday, April 28, 2016, 46 U.S. common stocks issued filings of shares being bought or sold by insiders. Highlighted Stocks Traded by Insiders: CarMax (KMX) - FREE Research Report Wyatt Natalie L, who is VP, Controller & PAO at CarMax, sold 1,366 shares at $55.18 on April 28, 2016. Following this transaction, the VP, Controller & PAO owned 1,603 shares meaning that the stake was reduced by 46.01% with the 1,366-share transaction. The shares most recently traded at $53.18, down $2.00, or 3.76% since the insider transaction. Historical insider transactions for CarMax go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,362
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 2,362
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 2,362
The average volume for CarMax has been 2.9 million shares per day over the past 30 days. CarMax has a market cap of $10.7 billion and is part of the services sector and specialty retail industry. Shares are down 0.07% year-to-date as of the close of trading on Thursday. CarMax, Inc., through its subsidiaries, operates as a retailer of used vehicles in the United States. The company operates in two segments, CarMax Sales Operations and CarMax Auto Finance. The company has a P/E ratio of 18.2. Currently, there are 7 analysts who rate CarMax a buy, no analysts rate it a sell, and 7 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on KMX - FREE TheStreet Quant Ratings rates CarMax as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full CarMax Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report Pratt Timothy A., who is EVP, GC & Chief Admin Officer at Boston Scientific, sold 39,927 shares at $21.40 on April 28, 2016. Following this transaction, the EVP, GC & Chief Admin Officer owned 291,724 shares meaning that the stake was reduced by 12.04% with the 39,927-share transaction. The shares most recently traded at $21.79, up $0.39, or 1.79% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 125,422
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 405,467
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 607,974
The average volume for Boston Scientific has been 10.0 million shares per day over the past 30 days. Boston Scientific has a market cap of $29.5 billion and is part of the health care sector and health services industry. Shares are up 18.38% year-to-date as of the close of trading on Thursday. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 15 analysts who rate Boston Scientific a buy, no analysts rate it a sell, and 5 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on BSX - FREE TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Libbey (LBY) - FREE Research Report Kovach Susan A, who is VP,General Counsel & Secretary at Libbey, sold 5,000 shares at $18.50 on April 28, 2016. Following this transaction, the VP,General Counsel & Secretary owned 39,881 shares meaning that the stake was reduced by 11.14% with the 5,000-share transaction. The shares most recently traded at $18.20, down $0.30, or 1.65% since the insider transaction. Historical insider transactions for Libbey go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 7,481
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 9,981
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 16,923
The average volume for Libbey has been 138,300 shares per day over the past 30 days. Libbey has a market cap of $371.5 million and is part of the consumer goods sector and consumer durables industry. Shares are down 12.15% year-to-date as of the close of trading on Thursday. Libbey Inc. manufactures and markets glass tableware products worldwide. The stock currently has a dividend yield of 2.69%. The company has a P/E ratio of 5.7. Currently, there are 2 analysts who rate Libbey a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on LBY - FREE TheStreet Quant Ratings rates Libbey as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, notable return on equity and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Libbey Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.